HK1110805A1 - 改進的 類似物及其使用方法 - Google Patents
改進的 類似物及其使用方法Info
- Publication number
- HK1110805A1 HK1110805A1 HK08105621.8A HK08105621A HK1110805A1 HK 1110805 A1 HK1110805 A1 HK 1110805A1 HK 08105621 A HK08105621 A HK 08105621A HK 1110805 A1 HK1110805 A1 HK 1110805A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- apo
- analogs
- methods
- improved
- use apo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60650604P | 2004-09-02 | 2004-09-02 | |
US60650704P | 2004-09-02 | 2004-09-02 | |
US60814804P | 2004-09-09 | 2004-09-09 | |
PCT/US2005/031431 WO2006029028A2 (en) | 2004-09-02 | 2005-09-02 | Improved apo e analogs and methods for their use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1110805A1 true HK1110805A1 (zh) | 2008-07-25 |
Family
ID=36036900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08105621.8A HK1110805A1 (zh) | 2004-09-02 | 2008-05-21 | 改進的 類似物及其使用方法 |
HK12104306.7A HK1163538A1 (zh) | 2004-09-02 | 2012-05-02 | 改進的 類似物和其使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12104306.7A HK1163538A1 (zh) | 2004-09-02 | 2012-05-02 | 改進的 類似物和其使用方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7947645B2 (zh) |
EP (3) | EP1796708A4 (zh) |
JP (2) | JP5052345B2 (zh) |
CN (2) | CN104558200B (zh) |
CA (1) | CA2578146C (zh) |
HK (2) | HK1110805A1 (zh) |
WO (1) | WO2006029028A2 (zh) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004097017A2 (en) | 2003-04-29 | 2004-11-11 | Avi Biopharma, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US7947645B2 (en) * | 2004-09-02 | 2011-05-24 | Cognosci, Inc. | APO E analogs and methods for their use |
US7572771B1 (en) | 2004-10-15 | 2009-08-11 | The United States Of America As Represented By The Departments Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
EP2052085B1 (en) * | 2006-12-21 | 2019-05-22 | Cognosci, Inc. | Methods for modulating set and uses thereof |
FR2915396B1 (fr) * | 2007-04-27 | 2012-01-20 | Vincience | Composition pharmaceutique et/ou cosmetique contenant des peptides |
FR2915397B1 (fr) * | 2007-04-27 | 2012-01-20 | Vincience | Composition pharmaceutique et/ou cosmetique contenant des principes actifs activateurs de l'aconitase |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
CA2692847A1 (en) | 2007-07-31 | 2009-02-05 | Cognosci, Inc. | Methods of inhibiting calcineurin with apoe analogs |
US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
WO2010002982A1 (en) | 2008-07-01 | 2010-01-07 | Cognosci, Inc. | Methods of treating cancer with apoe peptides |
PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
US20130005645A1 (en) * | 2010-01-06 | 2013-01-03 | Vitek Michael P | Apoe peptide dimers and uses thereof |
EP2605790B1 (en) * | 2010-08-16 | 2020-07-08 | The Trustees of Columbia University in the City of New York | Intranasal delivery of cell permeant therapeutics |
JP2012102054A (ja) * | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
JP2014511174A (ja) | 2011-02-07 | 2014-05-15 | ネオトープ バイオサイエンシーズ リミテッド | Apoe免疫療法 |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
WO2013033260A1 (en) * | 2011-08-29 | 2013-03-07 | The Regents Of The University Of California | Use of hdl-related molecules to treat and prevent proinflammatory conditions |
JP6031718B2 (ja) * | 2011-09-20 | 2016-11-30 | 国立大学法人 熊本大学 | リポ蛋白を用いたα2−マクログロブリンの神経保護抑制効果抑止剤及び眼科用組成物 |
US10882890B2 (en) * | 2014-07-25 | 2021-01-05 | Academia Sinica | Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates |
CN107074923B (zh) | 2014-07-31 | 2021-08-03 | Uab研究基金会 | Apoe模拟肽及对清除血浆胆固醇的较高效力 |
US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
JP5881801B2 (ja) * | 2014-10-29 | 2016-03-09 | 協同乳業株式会社 | 腸内ポリアミン増強剤 |
US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES |
WO2017136536A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
CN106890315B (zh) * | 2017-03-16 | 2019-09-06 | 北京热休生物技术有限公司 | Apo-e蛋白及其多肽在治疗与预防癌症中的应用 |
US20190022166A1 (en) * | 2017-07-18 | 2019-01-24 | Creative Bio-Peptides Inc. | Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders |
CN109942714B (zh) * | 2019-04-02 | 2022-07-08 | 中国药科大学 | 一种功能多肽及应用 |
CN111617232B (zh) * | 2020-06-04 | 2023-04-18 | 安域生物科技(杭州)有限公司 | 一类ApoE受体蛋白短肽阻断剂在阿尔茨海默病的应用 |
JP2023532490A (ja) * | 2020-06-26 | 2023-07-28 | リー、フェンチァオ | 環状ペプチド化合物及び使用方法 |
WO2022087669A1 (en) * | 2020-10-28 | 2022-05-05 | The Florey Institute Of Neuroscience And Mental Health | Peptide-based delivery of agents |
CN112837764B (zh) * | 2021-01-21 | 2023-07-07 | 北京晶泰科技有限公司 | 分子杂交方法及平台 |
CN113230382B (zh) * | 2021-04-29 | 2022-03-04 | 王丽琨 | 载脂蛋白E受体模拟肽6KApoEp在制备治疗脑出血后继发性脑损伤药物中的应用 |
CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5204327A (en) | 1988-11-18 | 1993-04-20 | Ashi Kasei Kogyo Kabushiki Kaisha | Treatment of cerebral edema with anp pharmaceutical compositions |
US5567682A (en) | 1988-12-16 | 1996-10-22 | Advanced Peptides And Biotechnology Sciences | Method of treating Alzheimer's disease |
US5473039A (en) | 1989-08-18 | 1995-12-05 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs |
US5182364A (en) | 1990-02-26 | 1993-01-26 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
ATE251886T1 (de) | 1993-08-31 | 2003-11-15 | Univ Duke | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit |
US5604198A (en) | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
EP0862460A4 (en) | 1995-10-17 | 2002-01-02 | Univ California | METHODS OF REDUCING THE INHIBITION OF APOLIPOPROTEIN E4-INDUCED NEURONAL REMODELING |
CA2251691A1 (en) * | 1996-03-26 | 1997-10-02 | Razvan T. Radulescu | Peptides with antiproliferative properties |
US6245751B1 (en) | 1996-07-09 | 2001-06-12 | University Of Cincinnati | Methods for the treatment of apolipoprotein E related diseases |
US6605588B1 (en) | 1996-11-27 | 2003-08-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
AU2997099A (en) * | 1998-03-11 | 1999-09-27 | Duke University | Methods of suppressing microglial activation |
US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
US20030077641A1 (en) * | 1998-03-11 | 2003-04-24 | Laskowitz Daniel T. | Methods of suppressing microglial activation and systemic inflammatory responses |
GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
WO2000025804A2 (en) * | 1998-11-02 | 2000-05-11 | The Regents Of The University Of California | A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
FR2786397B1 (fr) * | 1998-11-30 | 2003-01-10 | Synt Em | Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc |
EP1137664A2 (en) * | 1998-12-10 | 2001-10-04 | Washington University | Protein transduction system and methods of use thereof |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
US20030105027A1 (en) | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
EP1495045B1 (en) * | 2002-03-29 | 2009-09-02 | Creagene, Inc. | Cytoplasmic transduction peptides and uses thereof |
US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
US8034762B2 (en) * | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
US7947645B2 (en) * | 2004-09-02 | 2011-05-24 | Cognosci, Inc. | APO E analogs and methods for their use |
-
2005
- 2005-09-02 US US11/661,777 patent/US7947645B2/en not_active Expired - Fee Related
- 2005-09-02 EP EP05802697A patent/EP1796708A4/en not_active Withdrawn
- 2005-09-02 EP EP11169606.8A patent/EP2382983B1/en not_active Not-in-force
- 2005-09-02 CN CN201410817820.XA patent/CN104558200B/zh active Active
- 2005-09-02 EP EP20130179863 patent/EP2801366A3/en not_active Withdrawn
- 2005-09-02 CA CA2578146A patent/CA2578146C/en not_active Expired - Fee Related
- 2005-09-02 CN CN200580038189.2A patent/CN101084002B/zh not_active Expired - Fee Related
- 2005-09-02 WO PCT/US2005/031431 patent/WO2006029028A2/en active Application Filing
- 2005-09-02 JP JP2007530422A patent/JP5052345B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-21 HK HK08105621.8A patent/HK1110805A1/zh not_active IP Right Cessation
-
2011
- 2011-04-28 US US13/096,423 patent/US8288335B2/en not_active Expired - Fee Related
- 2011-08-03 JP JP2011169719A patent/JP5550612B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-02 HK HK12104306.7A patent/HK1163538A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2008511680A (ja) | 2008-04-17 |
EP2801366A2 (en) | 2014-11-12 |
US20090042783A1 (en) | 2009-02-12 |
EP2382983A1 (en) | 2011-11-02 |
CN104558200A (zh) | 2015-04-29 |
EP2382983B1 (en) | 2014-02-12 |
CN101084002A (zh) | 2007-12-05 |
US20110306550A1 (en) | 2011-12-15 |
WO2006029028A2 (en) | 2006-03-16 |
CN101084002B (zh) | 2015-01-21 |
EP1796708A2 (en) | 2007-06-20 |
JP2011256192A (ja) | 2011-12-22 |
JP5052345B2 (ja) | 2012-10-17 |
EP1796708A4 (en) | 2009-07-08 |
EP2801366A3 (en) | 2015-04-29 |
JP5550612B2 (ja) | 2014-07-16 |
CN104558200B (zh) | 2021-11-16 |
WO2006029028A3 (en) | 2007-01-18 |
CA2578146A1 (en) | 2006-03-16 |
CA2578146C (en) | 2017-03-28 |
HK1163538A1 (zh) | 2012-09-14 |
US7947645B2 (en) | 2011-05-24 |
US8288335B2 (en) | 2012-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1110805A1 (zh) | 改進的 類似物及其使用方法 | |
EP1773871A4 (en) | COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES | |
ZA200700357B (en) | Tetrapetide analogs | |
AP2006003768A0 (en) | TetraazabenzoÄeÜazulene derivatives and analogs tehereof | |
EG24318A (en) | Platform | |
IL180487A0 (en) | Medicament | |
GB0418540D0 (en) | Use | |
SG119251A1 (en) | Methods | |
EP1781302A4 (en) | NEW USE | |
GB0407301D0 (en) | Use | |
GB0410015D0 (en) | Use | |
GB0403629D0 (en) | Methods | |
GB0423552D0 (en) | Methods | |
GB0412878D0 (en) | Use | |
GB0415116D0 (en) | Catapult | |
GB0415757D0 (en) | Methods | |
GB0424494D0 (en) | Use | |
GB0426942D0 (en) | Medicament | |
GB0409098D0 (en) | Medicament | |
GB0406479D0 (en) | Methods | |
GB0413206D0 (en) | Methods | |
GB0401514D0 (en) | Methods | |
GB0401085D0 (en) | Methods | |
SG120191A1 (en) | Methods | |
GB0426632D0 (en) | Methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220826 |